Skip to main content
NCBI home page
The Kaohsiung Journal of Medical Sciences logoLink to The Kaohsiung Journal of Medical Sciences
. 2009 Jul 13;20(6):273–278. doi: 10.1016/S1607-551X(09)70118-4

Relationships Between American Urological Association Symptom Index, Prostate Volume, and Disease‐Specific Quality of Life Question in Patients with Benign Prostatic Hyperplasia

Chia‐Chu Liu 1, Chii‐Jye Wang 1,✉, Shu‐Pin Huang 1, Yii‐Her Chou 1, Wen‐Jeng Wu 1, Chun‐Hsiung Huang 1
PMCID: PMC11917967  PMID: 15253468

Abstract

The American Urological Association (AUA) symptom index is both valid and reliable in identifying the need to treat patients with benign prostatic hyperplasia (BPH) and in monitoring their response to therapy. We evaluated the relationships between AUA symptom index, disease‐specific quality of life question, and prostate volume in patients with BPH. A total of 100 patients who came to Kaohsiung Medical University Hospital, Taiwan, for help due to lower urinary tract symptoms (LUTS) and who were diagnosed with BPH between October 2002 and June 2003 were included in the study. All patients were evaluated using transrectal ultrasonography, AUA symptom index, and disease‐specific quality of life question. The disease‐specific quality of life question showed good correlation with AUA symptom score (r = 0.815, p < 0.01), but weak correlation with prostate volume (r = 0.225, p < 0.05) and age (r = 0.274, p < 0.05). Prostate volume had weak correlation with AUA symptom score (r = 0.251, p < 0.05) and age (r = 0.472, p < 0.01), but good correlation with prostate specific antigen (r = 0.638, p < 0.01). In addition to AUA symptom index, we suggest using the disease‐specific quality of life question to evaluate the influence on quality of life and response to treatment in clinical practice. Moreover, we should assess the impact of BPH symptoms rather than the increase in prostate volume during the management of BPH.

Keywords: benign prostatic hyperplasia, ultrasonography, symptoms, aging

Full Text

The Full Text of this article is available as a PDF (221.8 KB).

References

  • 1. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population‐based survey of urinary symptoms. J Urol. 1993; 150: 85–89. [DOI] [PubMed] [Google Scholar]
  • 2. Borth CS, Beiko DT, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: a decade of change. Urology. 2001; 57: 1082–1086. [DOI] [PubMed] [Google Scholar]
  • 3. Nickel JC. Long‐term implications of medical therapy on benign prostatic hyperplasia end points. Urology. 1998; 51 (Suppl 4A): 50–57. [DOI] [PubMed] [Google Scholar]
  • 4. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992; 148: 1549–1557. [DOI] [PubMed] [Google Scholar]
  • 5. O'Leary MP, Barry MJ, Fowler FJ Jr. Hard measures of subjective outcomes: validating symptom indexes in urology. J Urol. 1992; 148: 1546–1548. [DOI] [PubMed] [Google Scholar]
  • 6. Bosch JL, Hop WC, Kirkels WJ, Schroder FH. The International Prostate Symptom Score in a community‐based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. Br J Urol. 1995; 75: 622–630. [DOI] [PubMed] [Google Scholar]
  • 7. Hartung H. Do alpha‐blockers prevent the occurrence of acute urinary retention?. Eur Urol. 2001; 39: 13–18. [DOI] [PubMed] [Google Scholar]
  • 8. Roberts RO, Jacobsen SJ, Rhodes T, et al. Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol. 1997; 157: 1711–1717. [DOI] [PubMed] [Google Scholar]
  • 9. Barry MJ, Cockett AT, Holtgrewe HL, et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 1993; 150: 351–358. [DOI] [PubMed] [Google Scholar]
  • 10. Barry MJ, Girman CJ, O'Leary MP, et al. Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical measurement of prostate disease. J Urol. 1995; 153: 99–103. [DOI] [PubMed] [Google Scholar]
  • 11. Fowler FJ Jr, Barry MJ. Quality of life assessment for evaluating benign prostatic hyperplasia treatment. Eur Urol. 1993; 24 (Suppl 1): 24–27. [DOI] [PubMed] [Google Scholar]
  • 12. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. Correlation of the American Urological Association symptom index with self‐administered versions of the Madsen‐Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. J Urol. 1992; 148: 1558–1563. [DOI] [PubMed] [Google Scholar]
  • 13. Lawerence K. Measurement properties of the AUA symptom score: a methodological clarification. Br J Urol. 1996; 77: 175–180. [DOI] [PubMed] [Google Scholar]
  • 14. AUA Practice Guidelines Committee . AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol. 2003; 170: 530–547. [DOI] [PubMed] [Google Scholar]
  • 15. Nitti VW, Kim Y, Combs AJ. Correlation of the AUA symptom index with urodynamics in patients with suspected benign prostatic hyperplasia. Neurourol Urodyn. 1994; 13: 521–529. [DOI] [PubMed] [Google Scholar]
  • 16. Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty‐five and seventy‐nine years of age. Urology. 1993; 42: 36–41. [DOI] [PubMed] [Google Scholar]
  • 17. Yalla SV, Sullivan MP, Lecamwasam HS, et al. Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism. J Urol. 1995; 153: 674–680. [PubMed] [Google Scholar]
  • 18. Sirls LT, Jay J, Kirkemo A. Does the American Urological Association symptom score correlate with urodynamic obstruction?. J Urol. 1995; 153: 275A [Abstract 187]. [Google Scholar]
  • 19. Chapple C, Woo HH, Rosario DJ, Fleet C. Correlation of IPSS symptom score with findings on video pressure‐flow studies. J Urol. 1995; 153: 275A [Abstract 188]. [Google Scholar]
  • 20. Chancellor MB, Rivas DA, Keeley MA, et al. Similarity of the American Urological Association Symptom Index among men with benign prostatic hyperplasia (BPH), urethral obstruction not due to BPH and detrusor hyperreflexia without outlet obstruction. Br J Urol. 1994; 74: 200–203. [DOI] [PubMed] [Google Scholar]
  • 21. McNeill JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978; 15: 340–345. [PubMed] [Google Scholar]
  • 22. Simpson RJ, Fisher W, Lee AJ, et al. Benign prostatic hyperplasia in an unselected community‐based population: a survey of urinary symptoms, bothersomeness and prostatic enlargement. Br J Urol. 1996; 77: 186–191. [DOI] [PubMed] [Google Scholar]
  • 23. Kojima M, Nava Y, Inoue W, et al. The American Urological Association symptom index for benign prostatic hyperplasia as a function of age, volume and ultrasonic appearance of the prostate. J Urol. 1997; 157: 2160–2165. [PubMed] [Google Scholar]
  • 24. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991; 338: 469–471. [DOI] [PubMed] [Google Scholar]
  • 25. Ukimura O, Kojima M, Inui E, et al. A statistical study of the American Urological Association symptom index for benign prostatic hyperplasia in participants of mass screening program for prostatic disease using transrectal sonography. J Urol. 1996; 156: 1673–1678. [PubMed] [Google Scholar]

Articles from The Kaohsiung Journal of Medical Sciences are provided here courtesy of Kaohsiung Medical University and John Wiley & Sons Australia, Ltd

RESOURCES